Remicade (infliximab) - J&J
Humira (adalimumab) - AbbVie
Tremfya (guselkumab) - J&J
tofacitinib - Generic mfg.
Stelara (ustekinumab) - J&J
Jyseleca (filgotinib) - Alfasigma, Gilead
Skyrizi (risankizumab-rzaa) - AbbVie, Boehringer Ingelheim
Simponi (golimumab) - J&J
Entyvio (vedolizumab) - Takeda
Zeposia (ozanimod) - BMS
Velsipity (etrasimod) - Pfizer
EFFECT-1LAT: Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population (clinicaltrials.gov) - Oct 16, 2026 - P=N/A | N=4000 | Active, not recruiting | Sponsor: Pfizer | Trial completion date: Jul 2026 ➔ Oct 2026 | Trial primary completion date: Jul 2026 ➔ Oct 2026 
Trial completion date • Trial primary completion date • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis
http://clinicaltrials.gov/ct2/show/NCT07177209
 
Oct 16, 2026
 
Prev Next